News Sentiment

SMMT sentiment intelligence

Summit Therapeutics PLC news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 56 Balanced news tone 59 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 13.81 Week of 17 Jul 2026
Weighted tone 56/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

80/100 classification confidence.

Company focus 51

directly relevant articles

Source quality 2

high-authority source matches

Trend context Trend inactive

-9.4% over one week, +0.4% over four weeks, trend inactive, and near fair-value range.

Latest direct headline Positive

Summit Therapeutics Refocuses on Oncology Drug After Antibiotic Sale

Market Reaction

Price moving ahead of tone

65/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 80/100 classification
One-week reaction -9.4% Price reacting lower
Trend fit Trend inactive 0.4% over four weeks
Fair value -2.4% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 21
Neutral 34
Negative 4

Relevance

Why the article matched

Direct first
Direct company coverage 51
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Market source 12
Stock Titan 7
Quartr 5
TradingView 4
simplywall.st 4
GuruFocus 3
Stock Traders Daily 3
BioSpace 2

Event Lens

What the news is about

Classified themes
Market update 32
Earnings 18
Regulatory and legal 4
Deals and strategy 2
Analyst action 2
Macro sensitivity 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 59
Streetwise Reports Direct company coverage

Summit Therapeutics Refocuses on Oncology Drug After Antibiotic Sale

Summit Therapeutics (SMMT; SUMM) has divested its investigational Phase 3 antibiotic, ridinilazole, to Biossil for up to US$104.5 million in milestones, signaling a strategic shift to focus entirely on its oncology drug, ivonescimab. This move comes as the company aims to capital

Tone
Positive 71/100
Event
Regulatory and legal
Published
17 Jul 2026 15:39
Source
Streetwise Reports
BioSpace Direct company coverage

Summit Therapeutics to Host Second Quarter 2026 Financial Results & Operational Progress Call on July 23, 2026

Summit Therapeutics Inc. (Nasdaq: SMMT) will host a conference call on Thursday, July 23, 2026, at 4:30 p.m. EDT to discuss its second-quarter 2026 financial results and operational progress. The biopharmaceutical oncology company, focused on developing medicinal therapies, will

Tone
Neutral 50/100
Event
Earnings
Published
16 Jul 2026 14:10
Source
BioSpace
Moomoo Direct company coverage

Press Release: Summit Therapeutics to Host Second Quarter 2026 Financial Results & Operational Progress Call on July 23, 2026

Summit Therapeutics announced it will host a conference call on July 23, 2026, to discuss its second quarter 2026 financial results and provide an update on operational progress. The call will offer investors and stakeholders insights into the company's recent performance and fut

Tone
Neutral 50/100
Event
Earnings
Published
16 Jul 2026 12:14
Source
Moomoo
Simply Wall Street Direct company coverage

The Bull Case For Summit Therapeutics (SMMT) Could Change Following Ridinilazole Sale And Royalty Deal

Summit Therapeutics has sold its investigational antibiotic ridinilazole to Biossil Inc. for an upfront payment of US$500,000, with potential future milestones up to US$104.5 million and tiered royalties. While this deal provides a potential long-term income stream and shifts foc

Tone
Positive 59/100
Event
Regulatory and legal
Published
15 Jul 2026 23:10
Source
Simply Wall Street
Market source Direct company coverage

Summit to Divest Late-Stage Antibiotic Drug to Biossil in $105M Deal

Summit Therapeutics has agreed to divest its antibiotic candidate, ridinilazole, to Biossil Inc. for an upfront payment of $500,000 and up to $104.5 million in milestone payments. This divestiture allows Summit to focus on its oncology pipeline, specifically the development of iv

Tone
Positive 60/100
Event
Deals and strategy
Published
15 Jul 2026 12:48
Source
Market source
BioSpace Direct company coverage

Summit Therapeutics Signs Agreement to Sell Phase III Asset Ridinilazole to Biossil, Inc.

Summit Therapeutics has entered an agreement to sell its investigational Phase III antibiotic, ridinilazole, to Biossil, Inc. The deal includes an upfront payment of $500,000 and up to $104.5 million in potential milestone payments and royalties. Ridinilazole is intended for the

Tone
Positive 63/100
Event
Regulatory and legal
Published
15 Jul 2026 11:09
Source
BioSpace
Investing.com Direct company coverage

Summit Therapeutics sells ridinilazole to Biossil for $500k

Summit Therapeutics has sold its investigational Phase III antibiotic, ridinilazole, to Biossil, Inc. for an upfront payment of $500,000, with potential milestone payments up to $104.5 million and tiered royalties. This sale allows Summit to focus on its core oncology strategy an

Tone
Neutral 50/100
Event
Regulatory and legal
Published
14 Jul 2026 23:10
Source
Investing.com
citybiz Direct company coverage

Summit Therapeutics Sells Phase III Antibiotic Ridinilazole to Biossil in Milestone Deal

Summit Therapeutics has sold its Phase III antibiotic, ridinilazole, to Biossil, Inc. for an upfront payment of $500,000 and potential milestone payments of up to $104.5 million. This divestment allows Summit to focus on its oncology pipeline, while Biossil plans to use its AI-en

Tone
Positive 65/100
Event
Deals and strategy
Published
14 Jul 2026 22:48
Source
citybiz
TradingView Direct company coverage

Price to earnings forward of Summit Therapeutics Inc – BMV:SMMT

This article provides financial information for Summit Therapeutics Inc. (SMMT) on the Mexican Stock Exchange, specifically its forward price-to-earnings ratio. The content is presented as a snapshot from TradingView, indicating no current trades and highlighting financial data a

Tone
Neutral 50/100
Event
Earnings
Published
14 Jul 2026 22:48
Source
TradingView
DirectorsTalk Interviews Direct company coverage

Summit Therapeutics Inc. (SMMT) Stock Analysis: Exploring an 87.99% Potential Upside in Biotechnology

Summit Therapeutics Inc. (SMMT), a leading biotechnology firm, shows significant potential with an 87.99% upside predicted by its average target price, despite current unprofitability. The company, focused on groundbreaking cancer therapies like ivonescimab, faces financial chall

Tone
Positive 64/100
Event
Analyst action
Published
13 Jul 2026 22:48
Source
DirectorsTalk Interviews
Stock Traders Daily Direct company coverage

Why (SMMT) Price Action Is Critical for Tactical Trading

This article analyzes Summit Therapeutics Inc. (NASDAQ: SMMT) with AI-generated trading strategies and multi-timeframe signal analysis. It highlights mixed sentiment, a mid-channel oscillation pattern, and an exceptional risk-reward setup targeting a 30.4% gain. The piece provide

Tone
Positive 67/100
Event
Market update
Published
12 Jul 2026 00:41
Source
Stock Traders Daily
Quartr Direct company coverage

Summit Therapeutics (SMMT) Q1 2025 earnings summary

Summit Therapeutics (SMMT) announced its Q1 2025 financial results, highlighting significant progress with its bispecific antibody ivonescimab, including expanded regulatory approval in China and positive Phase III trial results for advanced NSCLC. The company ended Q1 2025 with

Tone
Positive 74/100
Event
Earnings
Published
10 Jul 2026 01:09
Source
Quartr
Quartr Direct company coverage

Summit Therapeutics (SMMT) Jefferies London Healthcare Conference 2025 Summary

This summary from the Jefferies London Healthcare Conference 2025 highlights Summit Therapeutics' focus on ivonescimab, a PD-1/VEGF bispecific antibody, for cancer treatment. With over 40,000 patients treated globally and 14 ongoing Phase III trials, ivonescimab has demonstrated

Tone
Positive 95/100
Event
Market update
Published
08 Jul 2026 20:51
Source
Quartr
Quartr Direct company coverage

Summit Therapeutics (SMMT) Status update Summary

Summit Therapeutics (SMMT) has presented strong HARMONi-6 Phase III trial results for Ivonescimab, demonstrating a statistically significant overall survival benefit in advanced squamous NSCLC compared to current treatments. The trial showed a hazard ratio of 0.66 with a median O

Tone
Positive 95/100
Event
Earnings
Published
08 Jul 2026 10:10
Source
Quartr
Quartr Direct company coverage

Summit Therapeutics (SMMT) Q4 2024 earnings summary

Summit Therapeutics (SMMT) reported its Q4 2024 earnings, highlighting significant progress for its drug ivonescimab, including a new clinical trial collaboration with Pfizer and Fast Track designation for a global Phase III trial. Financially, the company ended 2024 with $412 mi

Tone
Positive 73/100
Event
Earnings
Published
08 Jul 2026 08:41
Source
Quartr
Quartr Direct company coverage

Summit Therapeutics (SMMT) Q3 2025 earnings summary

Summit Therapeutics (SMMT) reported its Q3 2025 earnings, highlighting positive clinical trial results for ivonescimab in advanced squamous non-small cell lung cancer which supports a planned BLA submission. Financially, the company ended the quarter with $238.6 million in cash,

Tone
Positive 64/100
Event
Earnings
Published
08 Jul 2026 08:41
Source
Quartr
TradingView Direct company coverage

Price to sales forward of Summit Therapeutics Inc. – NASDAQ:SMMT

This article focuses on the "Price to sales forward" metric for Summit Therapeutics Inc. (NASDAQ: SMMT). It presents this financial data point within the context of the company's profile on TradingView. The visible content is limited to the title and basic navigational elements.

Tone
Neutral 50/100
Event
Market update
Published
07 Jul 2026 21:09
Source
TradingView
TradingView Direct company coverage

Price to book forward of Summit Therapeutics Inc. – NASDAQ:SMMT

The article provides a snapshot of the "Price to book forward" metric for Summit Therapeutics Inc. (NASDAQ: SMMT) on TradingView. It appears to be a financial data point from a larger financial overview of the company, showing its value and change percentages. Most of the content

Tone
Neutral 50/100
Event
Market update
Published
07 Jul 2026 10:40
Source
TradingView
TradingView Direct company coverage

Enterprise value to revenue forward of Summit Therapeutics Inc. – NASDAQ:SMMT

This page from TradingView provides a financial overview of Summit Therapeutics Inc. (NASDAQ: SMMT), focusing on its enterprise value to revenue forward metric. It indicates that the market was closed with no trades at the time of viewing. The content includes general financial a

Tone
Neutral 50/100
Event
Earnings
Published
07 Jul 2026 03:12
Source
TradingView
Stock Titan Direct company coverage

If You Invested $1,000 in Summit Therapeutics Inc (SMMT)

This article provides details on the historical performance of investing $1,000 in Summit Therapeutics Inc. (SMMT) over various periods, showing returns and compound annual growth rates. It also gives an overview of Summit Therapeutics, highlighting its focus on oncology, its lea

Tone
Neutral 50/100
Event
Macro sensitivity
Published
04 Jul 2026 02:10
Source
Stock Titan
Stock Traders Daily Direct company coverage

Understanding Momentum Shifts in (SMMT)

Quantitative Research Desk has analyzed Summit Therapeutics Inc. (NASDAQ: SMMT), indicating stable neutral readings in shorter horizons may signal an easing of a long-term weak bias. The analysis highlights an exceptional risk-reward setup targeting a 30.3% gain versus 0.3% risk,

Tone
Neutral 50/100
Event
Market update
Published
01 Jul 2026 05:40
Source
Stock Traders Daily